Physician profile
Gerald Plovsky
NPI 1982641858
$44,049.99
in general payments reported to CMS, 2019-2025
39 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,521 · 2020: $1,153 · 2021: $2,684 · 2022: $2,789 · 2023: $3,939 · 2024: $19K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $8,001 · Education: $50.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,851.50 |
| Food and Beverage | $8,000.54 |
| Education | $50.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $28,313.89 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,699.76 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,581.85 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $1,515.43 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Validus Pharmaceuticals LLC | $1,127.06 | 2019-2022 | |
| Axsome Therapeutics, INC. | $1,008.33 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $930.56 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $779.46 | 2021-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $768.44 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $715.49 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $621.87 | 2019-2025 | Fanapt, Hetlioz |
| Acadia Pharmaceuticals INC | $468.08 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $459.81 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Tris Pharma INC | $455.36 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Bausch Health US, LLC | $418.28 | 2019-2023 | Wellbutrin, Aplenzin |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $385.89 | 2022-2025 | Azstarys, Adlarity |
| E.R. Squibb & Sons, L.L.C. | $304.98 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $301.06 | 2019-2025 | Trintellix |
| Allergan, INC. | $272.84 | 2019-2020 | |
| Eisai INC. | $204.32 | 2020-2021 | |
| Indivior INC. | $193.19 | 2022-2023 | Perseris, Sublocade |
| Avanir Pharmaceuticals, INC. | $187.50 | 2019-2022 | |
| Almatica Pharma LLC | $177.55 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Braeburn INC. | $162.50 | 2024-2025 | Brixadi |
| Mdd US Operations, LLC | $142.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $112.15 | 2019-2022 | |
| Noven Therapeutics, LLC | $111.42 | 2020-2025 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $101.76 | 2022-2025 | Qelbree |
| Biogen, INC. | $100.00 | 2024 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $84.85 | 2023-2024 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $68.17 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $52.82 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $52.78 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $37.83 | 2019 | |
| Shire North American Group INC | $35.18 | 2019 | |
| Uswm, LLC | $31.74 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $27.86 | 2020-2021 | |
| Avion Pharmaceuticals | $22.84 | 2023 | Methylphenidate Hydrochloride |
| Collegium Pharmaceutical, INC. | $14.71 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Plovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.